^
Association details:
| Biomarker: | HER-2 amplification + KRAS wild-type |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Perjeta (pertuzumab) (HER2 dimerization inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors
Published date:
10/04/2023
Excerpt:
We assessed pertuzumab + trastuzumab in a tissue-agnostic cohort of adult patients...Activity was higher in those with wild-type (ORR, 28.1%) versus mutated KRAS (ORR, 7.1%)...Responses were observed in all tumor groups of patients with HER2 amplification and/or overexpression (Fig 1D). Among the 203 patients with KRAS wild-type tumors, ORR was 63.6% (7/11) for salivary cancer (including two CRs; one ongoing at data cutoff); 31.9% (22/69) for CRC, including one CR; 30.6% (11/36) for biliary cancer; 22.7% (5/22) for NSCLC; and 21.1% (4/19) for urothelial cancer...
DOI:
10.1200/JCO.22.02636
Trial ID:
